Latest KFF Health News Stories
These Secret Safety Panels Will Pick the COVID Vaccine Winners
Data and safety monitoring boards work under a cloak of secrecy meant to prevent undue influence by stakeholders, such as companies or the government. In the Trump era, some worry the anonymity could actually invite it.
It’s Not Just Insulin: Lawmakers Focus on Price of One Drug, While Others Rise Too
While insulin is the poster child for outrageous prescription costs, patients are paying ever more to treat depression, asthma, HIV, cholesterol and more. And the pandemic has overtaken efforts to force the issue in Congress.
Señales de una “vacuna sorpresa en octubre” alarma a científicos de carrera
El presidente Donald Trump, que parece decidido a anunciar una vacuna para COVID-19 antes de las elecciones, podría autorizarla legalmente a pesar de las objeciones.
Signs of an ‘October Vaccine Surprise’ Alarm Career Scientists
President Donald Trump has the legal power to authorize a COVID vaccine over the objections of the Food and Drug Administration and vaccine manufacturers. Such a move could further erode public trust in a vaccine and foist an unsafe shot on Americans.
¿Regalo para Florida? Trump aprobaría pronto importación de medicamentos de Canadá
A pesar de las objeciones de las farmacéuticas, se espera que la administración Trump finalice pronto el plan que permitiría a los estados importar medicamentos de venta bajo receta.
Election Gift for Florida? Trump Poised to Approve Drug Imports From Canada
The Trump administration is primed to approve a plan designed to help lower costs of some prescription drugs by allowing states to import them from Canada. The announcement could come before Election Day, and Florida appears to be in line to go first.
KHN’s ‘What the Health?’: It’s Scandal Week
President Donald Trump this week issued a prescription drug pricing order unlikely to lower drug prices, and he contradicted comments by his director of the Centers for Disease Control and Prevention on the need for mask-wearing and predictions for vaccine availability. Meanwhile, scandals erupted at the CDC, the Centers for Medicare & Medicaid Services and the Food and Drug Administration. And the number of people without health insurance grew in 2019, reported the Census Bureau, even while the economy soared. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss this and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
COVID Vaccine Trials Move at Warp Speed, But Recruiting Black Volunteers Takes Time
The National Institutes of Health has suggested minorities should be overrepresented in COVID-19 vaccine trials — perhaps at rates that are double their percentage of the U.S. population. But efforts to recruit patients from racial minority groups are just beginning, while some trials have already advanced to phase 3.
Los NIH, “muy preocupados” por efectos secundarios en ensayo de vacuna para COVID
La Administración de Alimentos y Medicamentos está evaluando la posibilidad de seguir a los reguladores británicos y reanudar el ensayo de la vacuna. Pero hay dudas.
NIH ‘Very Concerned’ About Serious Side Effect in Coronavirus Vaccine Trial
The AstraZeneca trial is on hold in the U.S. as scientists try to unravel whether a rare neurological condition is linked to the vaccine. But regulators are frustrated by a lack of information from the drugmaker.
Fauci Says COVID Vaccine Trials Could End Early If Results Are Overwhelming
The nation’s top infectious disease official is confident that an independent panel will base vaccine approval on science, not politics.
Fauci dice que una vacuna contra COVID podría estar lista antes de lo esperado
El experto en enfermedades infecciosas de más alto rango en el país dice que esto podría ocurrir si los ensayos clínicos en curso producen resultados abrumadoramente positivos.
California Rx: State May Dive Into Generic Drug Market
California could become the first state to develop its own line of generic drugs under a bill approved Monday by the legislature. The measure heads to Gov. Gavin Newsom for consideration.
Republican Convention, Day 4: Fireworks … and Shining a Light on Trump’s Claims
Donald Trump accepted his party’s nomination to seek reelection for a second term as president in front of a partisan audience that appeared to largely lack masks and opt against social distancing.
Trump Again Claims He’s Bringing Down Drug Prices, But Details of How Are Skimpy
During his Monday speech at the Republican National Convention, President Donald Trump pointed to his two of his recent executive orders as likely to lead to big reductions in prescription drug costs.
LA Hospital Seeks Vaccine Trial Participants Among Its Own High-Risk Patients
Harbor-UCLA Medical Center serves patients who are especially vulnerable to the coronavirus: They are essential workers, have chronic diseases and are members of underrepresented racial and ethnic groups. When the safety-net hospital kicks off enrollment for its COVID-19 vaccine trial Wednesday, it will look to those patients to participate.
Democratic Convention, Night 4: ‘Facts Over Fiction’ in Biden’s Speech
The impact of the novel coronavirus, and the current administration’s response to it, were central themes in Joe Biden’s presidential nomination acceptance speech.
KHN’s ‘What the Health?’: Kamala Harris on Health
The Democratic presidential ticket is complete, with Joe Biden’s selection of California Sen. Kamala Harris as his running mate. Health has not been a major issue for Harris, whose career priority has been the criminal justice system. But expect Republicans to pounce on her on-again, off-again support for “Medicare for All.” Meanwhile, with Congress still in a stalemate over another round of COVID-19 relief, President Donald Trump is trying to use his executive power to do what lawmakers have not — with mixed success. Kimberly Leonard of Business Insider, Joanne Kenen of Politico and Mary Agnes Carey of KHN join KHN’s Julie Rovner to discuss this and more. Plus, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
What Seniors Can Expect as Their New Normal in a Post-Vaccine World
Experts say folks 60 and up must continue to limit exposure in the years to come — even after there is a vaccine for COVID-19.
Fauci Unfazed as Scientists Rely on Unproven Methods to Create COVID Vaccines
Teams are starting to test vaccines using messenger RNA or chimpanzee cold viruses to inoculate humans. Will their benefits last?
